3 Stocks Underperforming Today In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 17,010 as of Monday, Sept. 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 891 issues advancing vs. 2,107 declining with 158 unchanged.

The Drugs industry currently sits down 2.0% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include NPS Pharmaceuticals ( NPSP), down 14.0%, Isis Pharmaceuticals ( ISIS), down 7.6%, Intercept Pharmaceuticals ( ICPT), down 5.8%, Jazz Pharmaceuticals ( JAZZ), down 4.9% and Pharmacyclics ( PCYC), down 3.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biogen Idec is down $6.61 (-2.0%) to $316.78 on average volume. Thus far, 553,685 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $315.71-$323.97 after having opened the day at $323.40 as compared to the previous trading day's close of $323.39.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $77.2 billion and is part of the health care sector. Shares are up 15.7% year-to-date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire